

## SUPPLEMENTAL TABLES

**Supplemental Table 1. Patients Achieving CR on the A+CHP Arm: Demographic and Pretreatment Characteristics**

	ALK- sALCL N=76		Non-sALCL N=38	
	SCT (n=27)	No SCT (n=49)	SCT (n=11)	No SCT (n=27)
<b>Male, n (%)</b>	16 (59)	24 (49)	6 (55)	15 (56)
<b>Age in years, median (range)</b>	50 (18-68)	59 (20-85)	57 (35-73)	66 (49,77)
<b>IPI score, n (%)</b>				
0-1	11 (41)	21 (43)	2 (18)	4 (15)
2-3	12 (44)	25 (51)	7 (64)	21 (78)
4-5	4 (15)	3 (6)	2 (18)	2 (7)
<b>Stage III/IV, n (%)</b>	22 (82)	31 (63)	11 (100)	23 (85)

A+CHP = brentuximab vedotin plus cyclophosphamide, doxorubicin, and prednisone; ALCL = anaplastic large cell lymphoma; ALK = anaplastic lymphoma kinase; CR = complete response; IPI: International Prognostic Index; sALCL = systemic ALCL; SCT = stem cell transplant

Note: There were no significant differences ( $p=0.49$ ) in the baseline IPI score distribution between patients who received SCT and patients who did not receive SCT.

**Supplemental Table 2. Patients Achieving CR on the A+CHP Arm: Use of Consolidative SCT after A+CHP in Patients with CR at EOT: Asia and Non-Asian Countries**

	ALK- sALCL N=76		Non-sALCL N=38	
	Asia n=10 (%)	Non-Asia n=66 (%)	Asia n=9 (%)	Non-Asia n=29 <sup>a</sup> (%)
<b>Intent to transplant at baseline, (%)</b>				
Yes	1 (10)	37 (56)	1 (11)	18 (62)
No	9 (90)	29 (44)	8 (89)	10 (34)
<b>Received consolidative SCT</b>				
Yes	1 (10)	26 (39)	1 (11)	10 (34)
No	9 (90)	40 (61)	8 (89)	19 (66)

<sup>a</sup> One patient had no response recorded for intention to transplant at baseline

A+CHP = brentuximab vedotin plus cyclophosphamide, doxorubicin, and prednisone; ALCL = anaplastic large cell lymphoma; ALK = anaplastic lymphoma kinase; CR = complete response; EOT = end of treatment; sALCL = systemic ALCL; SCT: stem cell transplant

**Supplemental Table 3. Patients Achieving CR on the A+CHP Arm: Summary of PFS by Consolidative SCT**

	ALK- sALCL N=76		Non-sALCL N=38		Combined N=114	
	SCT (n=27)	No SCT (n=49)	SCT (n=11)	No SCT (n=27)	SCT (n=38) <sup>a</sup>	No SCT (n=76)
<b>Estimated PFS at 3 years, % (95% CI)</b>	85.0 (64.9-94.1)	62.4 (46.4-74.8)	70.1 (32.3-89.5)	41.7 (22.4-59.9)	80.4 (62.9-90.2)	54.9 (42.4-65.8)
<b>Estimated PFS at 5 years, % (95% CI)</b>	75.6 (46.6- 90.2)	51.5 (31.6- 68.3)	56.1 (19.5-81.5)	35.7 (17.0-55.0)	65.3 (38.7-82.6)	46.4 (32.3-59.3)
<b>Univariate, HR (95% CI)</b>	0.35 (0.13-0.98)		0.46 (0.15-1.41)		0.36 (0.17-0.77)	
<b>Multivariate, HR (95% CI) adjusted for:</b>						
Age (<65, ≥65)	0.43 (0.15-1.23)		0.44 (0.14-1.39)		0.40 (0.18-0.88)	
Region (ROW, Asia)	0.36 (0.13-1.00)		0.47 (0.15-1.48)		0.36 (0.17-0.79)	
Age + Region	0.44 (0.15-1.27)		0.45 (0.14-1.44)		0.41 (0.18-0.90)	
<b>Median PFS, months (95% CI)</b>	NR (43.04-NR)	NR (19.88-NA)	62.26 (23.72-NA)	32.33 (8.08-NA)	NR (49.81-NA)	55.66 (19.88-NA)

Table presents HR of PFS for patients who achieved CR on A+CHP, SCT vs no SCT; HR<1 favors SCT; all HRs were stratified for baseline IPI score (0-1, 2-3, 4-5).

A+CHP = brentuximab vedotin plus cyclophosphamide, doxorubicin, and prednisone; ALCL = anaplastic large cell lymphoma; ALK = anaplastic lymphoma kinase; CI = confidence interval; CR = complete response; EOT = end of treatment; HR = hazard ratio; IPI: International Prognostic Index; ROW = rest of world; sALCL = systemic ALCL; PFS = progression-free survival; SCT: stem cell transplant

<sup>a</sup>Includes 2 allogeneic SCTs.

**Supplemental Table 4. Patients Achieving CR on the CHOP Arm: Demographic and Pretreatment Characteristics**

	ALK- sALCL N=53		Non-sALCL N=44	
	SCT (n=13)	No SCT (n=40)	SCT (n=16)	No SCT (n=28)
<b>Male, n (%)</b>	11 (85)	28 (70)	7 (44)	16 (57)
<b>Age in years, median (range)</b>	51 (24-71)	57 (19-79)	58 (41-70)	71 (40,82)
<b>IPI score, n (%)</b>				
0-1	4 (31)	16 (41)	4 (25)	6 (21)
2-3	9 (69)	19 (48)	9 (56)	19 (68)
4-5	0 (0)	5 (13)	3 (19)	3 (11)
<b>Stage III/IV, n (%)</b>	10 (77)	23 (58)	14 (88)	21 (75)

ALCL = anaplastic large cell lymphoma; ALK = anaplastic lymphoma kinase; CHOP = cyclophosphamide, doxorubicin, vincristine, and prednisone; CR = complete response; IPI: International Prognostic Index; sALCL = systemic ALCL; SCT = stem cell transplant

**Supplemental Table 5. Patients Achieving CR on the CHOP Arm: Use of Consolidative SCT after CHOP in Patients with CR at EOT: Asia and Non-Asian Countries**

	ALK- sALCL N=53		Non-sALCL N=44	
	Asia n=14 (%)	Non-Asia n=39 (%)	Asia n=12 (%)	Non-Asia n=32 (%)
<b>Intent to transplant at baseline, (%)</b>				
Yes	6 (43)	20 (51)	1 (8)	17 (53)
No	8 (57)	19 (49)	11 (92)	15 (47)
<b>Received consolidative SCT</b>				
Yes	1 (7)	12 (31)	2 (17)	14 (44)
No	13 (93)	27 (69)	10 (83)	18 (56)

ALCL = anaplastic large cell lymphoma; ALK = anaplastic lymphoma kinase; CHOP = cyclophosphamide, doxorubicin, vincristine, and prednisone; CR = complete response; EOT = end of treatment; sALCL = systemic ALCL; SCT = stem cell transplant

**Supplemental Table 6. Patients Achieving CR on the CHOP Arm: Summary of PFS by Consolidative SCT**

	ALK- sALCL N=53		Non-sALCL N=44		Combined N=97	
	SCT (n=13)	No SCT (n=40)	SCT (n=16)	No SCT (n=28)	SCT (n=29)	No SCT (n=68)
<b>Estimated PFS at 3 years, % (95% CI)</b>	58.6 (26.7-80.6)	62.7 (45.2-76.0)	73.7 (44.1-89.2)	42.9 (24.6-60.0)	67.2 (46.3-81.5)	54.1 (41.2-65.3)
<b>Estimated PFS at 5 years, % (95% CI)</b>	58.6 (26.7-80.6)	55.7 (35.2-72.1)	43.0 (8.8-74.6)	42.9 (24.6-60.0)	48.9 (21.6-71.6)	50.9 (37.4-62.9)
<b>Univariate, HR (95% CI)</b>	0.67 (0.24-1.89)		0.57 (0.22-1.47)		0.63 (0.32-1.24)	
<b>Multivariate, HR (95% CI) adjusted for:</b>						
Age (<65, ≥65)	0.77 (0.27-2.19)		0.93 (0.32-2.70)		0.78 (0.39-1.58)	
Region (ROW, Asia)	0.79 (0.27-2.35)		0.51 (0.20-1.34)		0.62 (0.31-1.27)	
Age + Region	0.92 (0.31-2.75)		0.84 (0.28-2.54)		0.80 (0.38-1.65)	
<b>Median PFS, months (95% CI)</b>	NR (24.54-NA)	63.80 (22.14-64.66)	55.92 (23.75-NA)	19.24 (8.80-61.96)	55.92 (32.03-NA)	60.75 (18.20-63.80)

Table presents HR of PFS for patients who achieved CR on CHOP, SCT vs no SCT; HR<1 favors SCT; all HRs were stratified for baseline IPI score (0-1, 2-3, 4-5).

ALCL = anaplastic large cell lymphoma; ALK = anaplastic lymphoma kinase; CHOP = cyclophosphamide, doxorubicin, vincristine, and prednisone; CI = confidence interval; CR = complete response; EOT = end of treatment; HR = hazard ratio; IPI: International Prognostic Index; ROW = rest of world; sALCL = systemic ALCL; PFS = progression-free survival; SCT: stem cell transplant